natgillin/translations-raw huggingface dataset:
Det resulterede i et fordelingsvolumen ved steady-state på 7,07 l.
3.35 resulting in a volume of distribution at steady state of 7.07.
Det resulterende volumen på 30 ml væske skal administreres i henhold til vejledningen fra fremstilleren af den nasogastriske sonde med passende efterskylninger.
30 mL of liquid should be administered as per the naso-gastric tube manufacturer’s instructions with appropriate water flushes.
Det rette antal hele eller halve tabletter, der skal bruges, beregnes ud fra hundens vægt.
The correct number of tablets or half tablets to use is calculated based on the dog’s weight.
Det røde lys aktiverer det fotosensibiliserende stof i Ameluz-gel.
Red light activates the medicine.
Det samlede billede er, at de hyppigste bivirkninger med ≥ 20 %, der er rapporteret ved sværhedsgrad 2 eller højere efter CTC (Common Terminology Criteria fra NCI i USA), er overfølsomhed, herunder anafylaktisk reaktion, febril neutropeni, anæmi, hyperglykæmi, nedsat blodpladetal, nedsat neutrofiltal og forhøjet bilirubinindhold i blodet.
Overall, the most common adverse reactions reported by CTC grade 2 and higher in the >=20% are hypersensitivity including anaphylactic reaction, febrile neutropenia, anaemia, hyperglycaemia platelet count decreased, neutrophil count decreased, blood bilirubin increased.
Det samlede billede var, at der sås komplet remission hos 30 patienter (46 %), delvis remission hos 7 patienter (11 %) og hæmatologisk forbedring hos 1 patient (2 %) i fem studier med 65 ALL-patienter, der fik behandling hvor Oncaspar indgik, hvor studierne blev analyseret ud fra den højeste terapeutiske respons i hele studiet.
Overall, from five studies analysed based on 65 ALL patients exposed to Oncaspar using the highest therapeutic response during the entire study, complete remission were observed in 30 patients (46%), partial remission in 7 patients (11%) and haematological improvement in 1 patient (2%).
Det samlede billede var, at i den gruppe, der fik Oncaspar, var hyppigheden af overfølsomhed af alle grader 9,8 %, 19,6 % havde anafylaktiske reaktioner og 5,9 % havde pancreatitis.
Overall, in the group receiving Oncaspar, all grade of hypersensitivity was 9.8%, anaphylactic reactions was 19.6%, and pancreatitis 5.9%.
Det samlede IGF-1-fordelingssvolumen (middel ± SD) efter subkutan indgivelse af INCRELEX hos 12 patienter med svær primær IGFD anslås til at være 0,257 (± 0,073) l/kg ved en mecasermindosis på
The total IGF-1 volume of distribution (mean ± SD) after subcutaneous administration of INCRELEX in 12 subjects with severe
Det samlede infunderede volumen fastsættes individuelt efter patientens vægt.
The total volume of infusion should be determined based on the individual’s patient weight.
Det samlede infusionsvolumen bestemmes af patientens kropsvægt.
The total volume of the infusion is determined by the patient’s body weight.
Det samlede injicerede mængde bør ikke overstige 50 µg tilmanocept og en total maksimal mængde radioak- tivitet på 74 MBq pr. dosis.
The total injection amount should not exceed 50 micrograms tilmanocept, with a total maximum radioactivity of 74 MBq per dose.
Det samlede natriumindhold i rekombinant humant hyaluronidase er 4,03 mg/ml.
The total sodium content of recombinant human hyaluronidase is 4.03 mg/ml.
Det samlede resultat af blødningshyppigheder i PLATO-studiet er vist i tabel 2.
Overall outcome of bleeding rates in the PLATO study are shown in Table 2.
Det samlede resultat af blødningshændelser i PEGASUS-studiet er vist i tabel 3.
Overall outcome of bleeding events in the PEGASUS study are shown in Table 3.
Det samlede resultat af de to undersøgelser var, at 87 % patienterne havde opnået fuld remission (45 af 52).
Looking at the results of the two studies together, 87% of the patients had complete remission (45 out of 52).
Det samlede resultatet af de fire undersøgelser viser, at Regranex heler ca.
What benefit has Regranex shown during the studies?
Det samlede tidsinterval mellem start på rekonstitutionen og færdiggørelse af den intravenøse infusionsvæske må ikke overstige 30 minutter.
The total time interval between starting reconstitution and completing preparation of the intravenous infusion should not exceed 30 minutes.
Det samlede volumen skal være 50 ml.
This should be a final volume of 50 ml.
Det samler sig i det knoglevæv,
It accumulates in bone
Det samme blev imidlertid ikke iagttaget ved forandrede områder i bugspytkirtel, nyrer, æggeledere eller blærehalskirtel.
However, this was not observed for lesions in the pancreas, kidney, ovary or prostate gland.
Det samme kan gøre sig gældende for ketamin og dextromethorphan (se også under punkt 4.4).
The same may be true for ketamine and dextromethorphan (see also section 4.4).
Det sammensatte endepunkt for bekræftede kardiovaskulære og cerebrovaskulære (CCV) hændelser [akut koronart syndrom (ACS), transitorisk iskæmisk attak (med billed-diagnosticeret infarkt), apopleksi eller CCV- død], var sammenligneligt for vildagliptin versus kombinerede aktive og placebo-komparatorer [Mantel-Haenszel risiko-ratio 0,84 (95 %-konfidensinterval 0,63-1,12)].
The composite endpoint of adjudicated cardiovascular and cerebrovascular (CCV) events [acute coronary syndrome (ACS), transient ischaemic attack (with imaging evidence of infarction), stroke or CCV death], was similar for vildagliptin versus combined active and placebo comparators [Mantel– Haenszel risk ratio 0.84 (95% confidence interval 0.63 1.12)].
Det sammensatte endepunkt for bekræftede kardiovaskulære og cerebrovaskulære (CCV) hændelser [akut koronart syndrom (ACS), transitorisk iskæmisk attak (med billed-diagnosticeret infarkt), apopleksi eller CCV- død], var sammenligneligt for vildagliptin versus kombinerede aktive og placebo-komparatorer [Mantel-Haenszel risiko-ratio 0,84 (95 %-konfidensinterval 0,63-1,12)].
The composite endpoint of adjudicated cardiovascular and cerebrovascular (CCV) events [acute coronary syndrome (ACS), transient ischaemic attack (with imaging evidence of infarction), stroke or CCV death], was similar for vildagliptin versus combined active and placebo comparators [Mantel– Haenszel risk ratio 0.84 (95% confidence interval 0.63-1.12)].
Det sekundære effektendepunkt var sammensat af recidiverende DVT, ikke-dødelig PE og død uanset årsag.
The secondary efficacy outcome was defined as the composite of recurrent DVT, non-fatal PE and all cause mortality.
Det sekundære effektmål var en global vurdering af forbedringen, foretaget af den undersøgende læge, ved brug af Activities of Daily Living (ADL) subskala til måling i ”off-periode” og UPDRS til måling af motorisk funktionsevne i ”on-periode”.
The secondary measures of efficacy included global assessments of improvement by the examiner, Activities of Daily Living (ADL) subscale scores when OFF and UPDRS motor while ON.
Det sekundære mål, fuldstændigt ophør af halsbrand, defineret som ingen halsbrand på patientens dagbogskort i 7 på hinanden følgende dage, var statistisk signifikant både i uge 1 (10,0 - 15,2 % versus placebo 0,9 - 2,4 %; p = 0,014 henholdsvis p<0,001 i de 2 studier) og i uge 2 (25,2 - 35,7 % versus placebo 3,4 - 9,0 %, p<0,001).
The secondary endpoint of complete resolution of heartburn, defined as no heartburn on the patient’s diary card for 7 consecutive days, was statistically significant at both week 1 (10.0% - 15.2% vs placebo 0.9% - 2.4%, p = 0.014, p<0.001) and week 2 (25.2% - 35.7% vs placebo 3.4% - 9.0%, p<0.001).
Det ser ud, som om disse problemer oftere opstår hos patienter, der i forvejen lider af en psykisk sygdom.
These problems tend to occur more often in those who have a history of mental illness.
Det seropositive niveau for anti-HAV-antistoffer efter Twinrix Voksen var 97 % både efter 7 og 48 måneder, mens det var 99 % og 93 % med GlaxoSmithKline Biologicals monovalente hepatitis A- vaccine og 99 % og 97 % efter en anden registreret monovalent hepatitis A-vaccine.
The seropositivity rate for anti-HAV antibodies after Twinrix Adult was 97% at both 7 and 48 months versus 99% and 93% after the GlaxoSmithKline Biologicals monovalent hepatitis A vaccine and 99% and 97% after another licensed monovalent hepatitis A vaccine.
Det ses hos 8% af personer, som tager Caprelsa mod medullær thyreoideacancer.
They are seen in 8% of people taking Caprelsa for medullary thyroid cancer.
Det ses hyppigere ved høje doser zidovudin (1.200 - 1.500 mg/dag) og hos patienter med dårlig knoglemarvsreserve forud for behandlingen, særligt ved fremskreden hiv-infektion.
These occurred more frequently at higher zidovudine doses (1200- 1500 mg/day) and in patients with poor bone marrow reserve prior to treatment, particularly with advanced HIV disease.
Det sikrer, at du får den rigtige mængde af medicinen.
This will make sure that you get the right amount of your medicine.
Det skal altid tages sammen med andre ordinerede antiepileptiske lægemidler efter en læges vejledning.
It should always be taken in combination with other prescribed antiepileptic medicines under the direction of a doctor.
Det skal anvendes i kombination med sikker sex, hvor der f.eks. anvendes kondomer.
It should be used in combination with safer sex practices, such as use of condoms.
Det skal anvendes sammen med en gelatinesvamp af godkendt type.
It must be used with an approved type of sponge made of gelatin.
Det skal bekræftes, at patientens identitet svarer til de obligatoriske, entydige patientoplysninger på Provenge-posen og på Final Product Disposition Notification- formularen.
It must be ensured that the patient’s identity matches the essential unique patient information on the Provenge bag and on the Final Product Disposition form.
Det skal bemærkes, at patienter med faktor IX-inhibitorer kan have en større risiko for anafylaxi ved efterfølgende behandlinger med faktor IX.
It should be noted that patients with factor IX inhibitors may be at an increased risk of anaphylaxis with subsequent challenge with factor IX.
Det skal besluttes om amning skal fortsætte/ophøre eller behandling med Mycamine skal fortsætte/ophøre, idet der tages hensyn til fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Mycamine should be made taking into account the benefit of breast-feeding to the child and the benefit of Mycamine therapy to the mother.
Det skal besluttes, om amning eller behandling med Aerivio Spiromax skal ophøre, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breastfeeding or to discontinue Aerivio Spiromax therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning eller behandling med Airexar Spiromax skal ophøre, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breastfeeding or to discontinue Aerivio Spiromax therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning eller behandling med Aranesp skal ophøre, idet der tages højde for fordelen ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Aranesp therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning eller behandling med ATryn skal ophøre, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ATryn therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning eller behandling med Fexeric skal ophøre, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Fexeric therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning eller behandling med filgrastim skal ophøre, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast- feeding or to discontinue/abstain from filgrastim therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning eller behandling med filgrastim skal ophøre, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from filgrastim therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning eller behandling med glycerolphenylbutyrat skal ophøre, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast- feeding or to discontinue/abstain from glycerol phenylbutyrate therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning eller behandling med Neulasta skal ophøre, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Neulasta therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning eller behandling med Rapiscan skal ophøre, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision should be made whether to discontinue breast- feeding or to abstain from Rapiscan administration taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning eller behandling med Rasilamlo skal ophøre, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Rasilamlo therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning eller behandling med Sivextro skal ophøre, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Sivextro therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning eller behandling med ZEPATIER skal ophøre, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ZEPATIER therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning skal fortsætte/ophøre, eller behandling med Respreeza skal fortsætte/ophøre, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele ved behandling med human alfa- 1-proteinasehæmmer for moderen.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Respreeza should be made, taking into account the benefit of breast-feeding to the child and the benefit of human alpha1- proteinase inhibitor therapy to the woman.
Det skal besluttes, om amning skal ophøre eller behandling med Abilify Maintena seponeres, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast- feeding or to discontinue/abstain from Abilify Maintena therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning skal ophøre eller behandling med AZOPT seponeres, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from AZOPT therapy taking in to account the benefit of breast- feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning skal ophøre eller behandling med epoetin alfa skal seponeres/undlades, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele af epoetin alfa for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy with epoetin alfa taking into account the benefit of breastfeeding for the child and the benefit of epoetin alfa therapy for the woman.
Det skal besluttes, om amning skal ophøre eller behandling med Fycompa seponeres, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Fycompa therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning skal ophøre eller behandling med LUMIGAN seponeres, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast- feeding or to discontinue from LUMIGAN therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning skal ophøre eller behandling med LUMIGAN seponeres, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue from LUMIGAN therapy taking into account the benefit of breast- feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning skal ophøre eller behandling med pregabalin seponeres, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue pregabalin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning skal ophøre eller behandling med saxagliptin seponeres, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy to the woman.
Det skal besluttes, om amning skal ophøre eller behandling med Taltz seponeres, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision should be made whether to discontinue breast-feeding or to discontinue Taltz taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning skal ophøre eller behandling med Zinforo seponeres/undgås, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Zinforo therapy taking into account the benefit of therapy for the woman.
Det skal besluttes, om amning skal ophøre, eller behandling med Incruse skal seponeres, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue Incruse therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning skal ophøre, eller behandling med Vipdomet seponeres, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Vipdomet therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Det skal besluttes, om amning skal ophøre, eller om Tecfidera skal seponeres.
A decision must be made whether to discontinue breast-feeding or to discontinue Tecfidera therapy.
Det skal de tage med i deres overvejelser, inden de behandler dig med Cyanokit. hvis du er blevet behandlet med Cyanokit og du skal have taget følgende: blod- eller urinprøver.
They will have to take it into account before treating you with Cyanokit. that you have been treated with Cyanokit if you need to have the following: any blood or urine tests.
DET SKAL DE VIDE FØR DE BEGYNDER AT TAGE SONATA
What you need to know before you take Sonata Do not take Sonata
DET SKAL DE VIDE, FØR DE BEGYNDER AT BRUGE ALIMTA Brug ikke ALIMTA: hvis De er overfølsom (allergisk) over for pemetrexed eller et af de øvrige indholdsstoffer i ALIMTA (angivet i punkt 6). hvis De ammer, skal De afbryde amningen under behandlingen med ALIMTA. hvis De for nylig er blevet eller snart skal vaccineres mod gul feber.
WHAT YOU NEED TO KNOW BEFORE YOU USE ALIMTA Do not use ALIMTA if you are allergic (hypersensitive) to pemetrexed or any of the other ingredients of ALIMTA (listed in section 6). if you are breast-feeding; you must discontinue breast-feeding during treatment with ALIMTA. if you have recently received or are about to receive a vaccine against yellow fever.
DET SKAL DE VIDE, FØR DE BEGYNDER AT BRUGE INTRINSA Brug ikke Intrinsa hvis De er overfølsom (allergisk) over for testosteron eller et af de øvrige indholdsstoffer (se pkt. ‘Yderligere oplysninger’ til sidst i denne indlægsseddel).
BEFORE YOU USE INTRINSA Do not use Intrinsa if you are allergic (hypersensitive) to testosterone or any of the other ingredients of Intrinsa (see section ‘Further information’ at the end of this leaflet).
DET SKAL DE VIDE, FØR DE BEGYNDER AT BRUGE KENTERA Brug ikke Kentera:
BEFORE YOU USE KENTERA Do not use Kentera:
DET SKAL DE VIDE, FØR DE BEGYNDER AT BRUGE LIVENSA Brug ikke Livensa hvis De er overfølsom (allergisk) over for testosteron eller et af de øvrige indholdsstofferLivens (se pkt. ‘Yderligere oplysninger’ til sidst i denne indlægsseddel).
BEFORE YOU USE LIVENSA Do not use Livensa if you are allergic (hypersensitive) to testosterone or any of the other ingredients of Livensa (see section ‘Further information’ at the end of this leaflet).
DET SKAL DE VIDE, FØR DE BEGYNDER AT BRUGE VELOSULIN Brug ikke Velosulin
BEFORE YOU USE VELOSULIN Do not use Velosulin
DET SKAL DE VIDE, FØR DE BEGYNDER AT BRUGE YTRACIS Brug ikke YTRACIS: hvis De er overfølsom (allergisk) over for yttriumchlorid (90Y) eller et af de øvrige indholdsstoffer i YTRACIS. hvis De er gravid, eller hvis der er mulighed for, at De er gravid (se nedenfor).
BEFORE YOU USE YTRACIS Do not use YTRACIS: if you are hypersensitive (allergic) to Yttrium (90Y) chloride or any of the other ingredients of YTRACIS. if you are pregnant or if there is a possibility that you might be pregnant (see below).
DET SKAL DE VIDE, FØR DE BEGYNDER AT TAGE AZILECT Tag ikke AZILECT hvis De er overfølsom (allergisk) over for rasagilin eller et af de øvrige indholdsstoffer i AZILECT hvis De lider af alvorlige leverlidelser
BEFORE YOU TAKE AZILECT Do not take AZILECT if you are allergic (hypersensitive) to rasagiline or any of the other ingredients of AZILECT. if you have severe liver problems.
DET SKAL DE VIDE, FØR DE BEGYNDER AT TAGE CARBAGLU Tag ikke Carbaglu :
BEFORE YOU TAKE CARBAGLU Do not take Carbaglu: